ESR1 and acute promyelocytic leukemia: The ability of small molecule hormones to regulate NR activity make them excellent pharmaceutical targets; for example, retinoic acid (a ligand for retinoic acid receptor alpha, RARα), the synthetic antagonist tamoxifen (a ligand for estrogen receptor alpha, ERα), dexamethasone (a ligand for glucocorticoid receptor alpha, GRα) or thiazolidinediones (ligands for peroxisome proliferator-activated receptor gamma, PPARγ) are used in acute promyelocytic leukemia, ERα-positive breast cancer, inflammatory disorders and type II diabetes, respectively[3].